Clinical outcomes and costs associated with the use of digoxin in atrial fibrillation and flutter were evaluated in a prospective, observational study at 18 academic in a prospective, observational study at 18 academic medical centers in the United States.
Data were collected on 115 patients (aged >18 years) with atrial fibrillation or flutter who were treated with digoxin for rapid ventricular rate (>120 beats/min).
The median time to ventricual rate control (i.e., resting ventricular rate <100 beats/min, decrease in ventricular rate of >20%, or sinus rhythm) was 11.6 hours from the first dose of digoxin for all evaluable patients (n=105) and 9.5 hours for those only receiving digoxin (n=64).
Mots-clés Pascal : Flutter auriculaire, Digoxine, Fibrillation auriculaire, Appareil circulatoire pathologie, Cardiopathie, Trouble rythme cardiaque, Trouble excitabilité, Economie santé, Digitalique, Antiarythmique, Chimiothérapie, Analyse coût, Etats Unis, Amérique du Nord, Amérique, Homme, Traitement, Efficacité traitement
Mots-clés Pascal anglais : Atrial flutter, Atrial fibrillation, Cardiovascular disease, Heart disease, Arrhythmia, Excitability disorder, Health economy, Digitalis drug, Antiarrhythmia agent, Chemotherapy, Cost analysis, United States, North America, America, Human, Treatment, Treatment efficiency
Notice produite par :
Inist-CNRS - Institut de l'Information Scientifique et Technique
Cote : 93-0644642
Code Inist : 002B02F02. Création : 199406.